Evidence map›Paper›PMID 31646273›Full record

ReviewCardiovascular endocrinology & metabolism2018

The impact of glucose-lowering medications on cardiovascular disease.

Angelo Avogaro, Saula Vigili De Kreutzenberg, Gian Paolo Fadini

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular endocrinology & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Angelo AvogaroDepartment of Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy.
Saula Vigili De KreutzenbergDepartment of Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy.
Gian Paolo FadiniDepartment of Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease. Metabolic control is mandatory both for preventing long-term complications and for reducing the negative effects of the exposure of the other risk factors. In this article, we will describe the most commonly used glucose-lowering agents, the pathophysiological mechanisms underlying their cardiovascular protection, the available evidence-based data for this protection, and the contraindications and potential adverse effects.

Indexed as

cardiovascular outcome trialsdiabetes type 2glucagon-like peptide 1 receptor agonistsmacrovascular complicationsmicrovascular complicationssodium–glucose cotransporters 2

Identifiers

PMID31646273
PMCPMC6739886
OpenAlexW2772752809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.